首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Design Formulation and Evaluation of Soluble Soft Gel Ocular Insert of Ketorolac Tromethamine using Modified Locust Bean Gum
【24h】

Design Formulation and Evaluation of Soluble Soft Gel Ocular Insert of Ketorolac Tromethamine using Modified Locust Bean Gum

机译:改性刺槐豆胶设计制备和评价酮咯酸三甲胺可溶性软凝胶眼用插件

获取原文
           

摘要

A major problem in ocular therapeutics is the attainment of optimal drug concentration at the site of action which is compromised mainly due to precorneal loss resulting in only a small fraction of the drug being ocularly absorbed. The effective dose administered may be altered by increasing the retention time of medication into the eye by using ocular inserts for treating various ocular diseases. The aim of the present study was to prepare and evaluate novel Ocular inserts of Ketorolac Tromethamine with polymers like HPMC K4M, PVA, Locust Bean Gum and Modified Locust Bean Gum with Glycerol as plasticizer by film casting method. Nine formulations of ocular inserts based on Comaprision Study On the basis of In vitro release studies & physicochemical parameters, the formulation MOG sustained with maximum cumulative of 97.244% for a period 12 hr and it was found to be better than other formulations; hence MOG 2% was selected as optimized formulation. In vitro drug release kinetic data revealed that all formulation followed near to zero order release kinetics, involving in the all formulation drug release by Super Case-II type of diffusion. Optimized formulation (MOG 12%) passed the test for sterility and in stability studies no change of physiological properties. On the basis of the present study, the ocular inserts of Ketorolac Tromethamine gives promising future for the ophthalmic drug delivery system.
机译:眼部治疗中的主要问题是在作用部位获得最佳药物浓度,这主要是由于角膜前损失造成的,这导致仅一小部分药物被眼部吸收而受到损害。通过使用用于治疗各种眼部疾病的眼用插入物来增加药物在眼中的保留时间,可以改变给药的有效剂量。本研究的目的是通过薄膜浇铸法制备和评价新型酮咯酸三甲胺与聚合物的共聚物,如HPMC K4M,PVA,刺槐豆胶和以甘油为增塑剂的改良刺槐豆胶。基于Comaprision研究的9种眼药水制剂在体外释放研究和理化参数的基础上,MOG制剂在12个小时内的最大累积持续率为97.244%,并且发现它优于其他制剂。因此,选择2%的MOG作为优化配方。体外药物释放动力学数据表明,所有制剂均遵循接近零级的释放动力学,涉及所有制剂通过Super Case-II型扩散释放。优化配方(MOG 12%)通过了无菌测试,并且在稳定性研究中未改变其生理特性。在本研究的基础上,酮咯酸三甲胺的眼用插入物为眼科给药系统提供了广阔的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号